CORVUS PHARMACEUTICALS INC (CRVS)
Health Care · Immunooncology and T cell-targeted therapeutics · NASDAQ
Clinical-stage biotech harnessing selective ITK inhibition to reprogram T cell immunity for treating T cell lymphomas, atopic dermatitis, and solid tumors.
What CORVUS PHARMACEUTICALS INC does
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing product candidates that target proteins critical to immune cell maturation and function. The company's lead candidate, soquelitinib (formerly CPI-818), is a selective, covalent ITK inhibitor designed to modulate T cell function for treating immune-mediated, inflammatory, and oncologic diseases. The pipeline includes soquelitinib in Phase 3 trials for relapsed T cell lymphomas and Phase 2 trials for atopic dermatitis, plus two additional candidates in clinical development for solid tumors.
Themes: ["Oncology / T cell lymphomas","Immunomodulation / T cell engineering","Atopic dermatitis and inflammatory diseases","Clinical-stage biopharmaceutical"]
Fundamentals
- Price$16.20 as of 2026-07-09 close
- Market cap$1.4B as of 2026-07-10
- 1-year return+287.6% as of 2026-07-09 close
- ROE-38.9% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.92 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: soquelitinib is in Phase 2/3 trials with no approved products, exposing the company to regulatory, efficacy, and safety uncertainties that could delay or halt development.","Capital requirements: as a clinical-stage company with no revenue, Corvus faces ongoing financing risk and depends on raising capital to fund continued clinical trials and operations.","Competitive landscape: ITK inhibitors and other T cell-targeted therapies are being pursued by larger pharmaceutical companies, creating intellectual property and market adoption risks."]
Competitors & peers
- Gilead Sciences (GILD)
- Celgene (now part of Bristol Myers Squibb) (BMY)
- Amgen (AMGN)
- Juno Therapeutics (part of Celgene/BMY)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.